Product Overview

Alternative Name: H2-GMZ

Development Status: Active Development

Target: Male

Mode: Non-hormonal

Delivery Type: Oral

Duration Type: Short-acting

Description: H2-Gamendazole rapidly acts via Sertoli cells by inducing a transient increase in interleukin 1A causing disruption of spermatid-Sertoli cell junctions. There is premature release of spermatids, which results in semen without sperm. Gamendazole, along with Adjudin, are derivatives of lonidamine.

Updated date: May 30, 2018

Vertical Tabs


Project Phase: Early Development

Project Stage: Pre-clinical

Status Details:
  • Contraceptive activity proven in rats after single oral dose in 3-6mg/kg range; high oral bioavailability. Identical blockage of late stage spermatogenesis proven in mice and rabbits; no-side effects observed to-date. Reversibility of infertility with multiple low dose regimens in rats and other species needs to be investigated.
  • First non-human primate pilot study started in 2010, looking at initial safety and proof of concept based on semen sperm count. Non-GLP pre-clinical toxicology (MTD, 7-day TOX, Toxicokinetics) also starting in 2010.

Download Product Report